Troponin

• 

  Subject Areas on Research

  • A 37-year-old man with chest pain, ECG changes, and elevated cardiac enzymes. 
  • A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. 
  • ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. 
  • Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. 
  • Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. 
  • Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator? 
  • An update on predictive biomarkers for major adverse cardiovascular events in patients undergoing vascular surgery. 
  • Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. 
  • Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. 
  • Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. 
  • Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. 
  • Beyond the cardiac myofilament: hypertrophic cardiomyopathy- associated mutations in genes that encode calcium-handling proteins. 
  • Biochemical markers in suspected acute myocardial infarction: the need for early assessment. 
  • Biological cross-reactivity of rat testis phosphodiesterase activator protein and rabbit skeletal muscle troponin-C. 
  • Biomarker guided therapy for heart failure: focus on natriuretic peptides. 
  • Calcium control of muscle phosphorylase kinase through the combined action of calmodulin and troponin. 
  • Calmodulin as an integral subunit of phosphorylase kinase from rabbit skeletal muscle. 
  • Calmodulin is intrinsically LESS effective than troponin C in activating skeletal muscle contraction. 
  • Calmodulin--an intracellular calcium receptor. 
  • Calmodulin-cardiac troponin C chimeras. Effects of domain exchange on calcium binding and enzyme activation. 
  • Can we prevent heart failure with exercise? 
  • Cardiac Biomarkers Predict Large Vessel Occlusion in Patients with Ischemic Stroke. 
  • Cardiac Troponin Testing as a Component of Return to Play Cardiac Screening in Young Competitive Athletes Following SARS-CoV-2 Infection. 
  • Cardiac markers in the assessment of acute coronary syndromes. 
  • Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. 
  • Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. 
  • Cardiac troponins in acute coronary syndromes. 
  • Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. 
  • Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. 
  • Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. 
  • Chicken perinatal troponin Ts are generated by a combination of novel and phylogenetically conserved alternative splicing pathways. 
  • Chimeric calmodulin-cardiac troponin C proteins differentially activate calmodulin target enzymes. 
  • Clinical Policy: Critical Issues in the Evaluation and Management of Emergency Department Patients With Suspected Non-ST-Elevation Acute Coronary Syndromes. 
  • Co-operative activation of skeletal muscle thin filaments by rigor crossbridges. The effect of troponin C extraction. 
  • Co-operative interactions between troponin-tropomyosin units extend the length of the thin filament in skeletal muscle. 
  • Combining necrosis and platelet markers for perfecting myocardial infarction rule out: how close are we? 
  • Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. 
  • Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). 
  • Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes. 
  • Control of microtubule assembly-disassembly by calcium-dependent regulator protein. 
  • Coordinate changes in fast thin filament and Z-line protein expression in the early response to chronic stimulation. 
  • Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. 
  • Current Controversies in Caring for the Critically Ill Pulmonary Embolism Patient. 
  • Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. 
  • Defining myocardial infarction: a work in progress: Ischaemic heart disease. 
  • Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). 
  • Discordant cardiac biomarkers: frequency and outcomes in emergency department patients with chest pain. 
  • Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes. 
  • Early Elevated Troponin Levels After Ischemic Stroke Suggests a Cardioembolic Source. 
  • Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. 
  • Effect of different troponin T-tropomyosin combinations on thin filament activation. 
  • Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. 
  • Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. 
  • Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review. 
  • Expression of a novel combination of fast and slow troponin T isoforms in rabbit extraocular muscles. 
  • Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Fluorescence changes on contractile activation in TnC(DANZ) labeled skinned rabbit psoas fibers. 
  • Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. 
  • HEART Failure? Episodes of Missed Major Cardiac Events When Applying the HEART Pathway to an Observation Unit Population. 
  • High-Sensitivity Troponin in Acute Heart Failure Triage. 
  • High-Sensitivity Troponin in Noncardiac Surgery: Pandora's Box or Opportunity for Precision Perioperative Care? 
  • High-sensitivity troponin assays: evidence, indications, and reasonable use. 
  • High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction. 
  • Identification of a fetal exon in the human fast troponin T gene. 
  • Identifying Low-risk Patients for Early Discharge From Emergency Department Without Using Subjective Descriptions of Chest Pain: Insights From Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) 3 and 4 Trials. 
  • Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. 
  • Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. 
  • Implementation of High-Sensitivity Cardiac Troponin Assays in the United States. 
  • Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. 
  • In patients with chest pain, HEART Pathway-guided and usual care did not differ for MACE or health care use. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. 
  • Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions. 
  • Interactions of calmodulin with coated vesicles from brain. 
  • Is there a rationale for antiplatelet therapy in acute heart failure? 
  • Ischemic Stroke with Troponin Elevation: Patient Characteristics, Resource Utilization, and In-Hospital Outcomes. 
  • Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. 
  • Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. 
  • Markers of cardiac ischemia, injury, and inflammation. 
  • Meta-analysis of cardiomyopathy-associated variants in troponin genes identifies loci and intragenic hot spots that are associated with worse clinical outcomes. 
  • Molecular analysis of calmodulin and smooth muscle myosin light chain kinase. 
  • N-terminal amino acid sequences of three functionally different troponin T isoforms from rabbit fast skeletal muscle. 
  • Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. 
  • National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. 
  • Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. 
  • Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω-3 Polyunsaturated Fatty Acids. 
  • Origin of fetal troponin T: developmentally regulated splicing of a new exon in the fast troponin T gene. 
  • Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study. 
  • Overcoming the challenges facing quality-improvement strategies for non-ST-segment elevation acute coronary syndromes. 
  • Patterns of troponin T expression in mammalian fast, slow and promiscuous muscle fibres. 
  • Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. 
  • Pharmacologically dosed oral glutamine reduces myocardial injury in patients undergoing cardiac surgery: a randomized pilot feasibility trial. 
  • Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. 
  • Physiologically regulated alternative splicing patterns of fast troponin T RNA are conserved in mammals. 
  • Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. 
  • Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. 
  • Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. 
  • Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). 
  • Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). 
  • Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. 
  • Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. 
  • SARS-CoV-2 and Stroke in a New York Healthcare System. 
  • Sequence homology of the Ca2+-dependent regulator of cyclic nucleotide phosphodiesterase from rat testis with other Ca2+-binding proteins. 
  • Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. 
  • Spectrum of ischemic heart disease and the role of biochemical markers. 
  • Structural changes in isometrically contracting insect flight muscle trapped following a mechanical perturbation. 
  • The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. 
  • The Management of Acute Chest Pain: What Lies Beyond the Emergency Department Doors? 
  • The aorta wall of patients presenting to the emergency department with acute myocardial infarction by cardiac magnetic resonance. 
  • The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). 
  • The diagnostic utility of cardiovascular magnetic resonance in patients with chest pain, elevated cardiac enzymes and non-obstructed coronary arteries. 
  • The extent of amino-terminal heterogeneity in rabbit fast skeletal muscle troponin T. 
  • The nontranscribed chicken calmodulin pseudogene cross-hybridizes with mRNA from the slow-muscle troponin C gene. 
  • The role of calmodulin in the structure and regulation of phosphorylase kinase from rabbit skeletal muscle. 
  • The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. 
  • The utility of troponin measurement to detect myocardial infarction: review of the current findings. 
  • Three-dimensional structure of calmodulin. 
  • Thrombolysis in myocardial infarction risk score in an observation unit setting. 
  • Transitions from fetal to fast troponin T isoforms are coordinated with changes in tropomyosin and alpha-actinin isoforms in developing rabbit skeletal muscle. 
  • Troponin Improves the Yield of Transthoracic Echocardiography in Ischemic Stroke Patients of Determined Stroke Subtype. 
  • Troponin T3 expression in skeletal and smooth muscle is required for growth and postnatal survival: characterization of Tnnt3(tm2a(KOMP)Wtsi) mice. 
  • Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. 
  • Troponin and other cardiac markers: role in management of acute coronary syndromes. 
  • Troponin criteria for myocardial infarction after percutaneous coronary intervention. 
  • Troponin elevation after black widow spider envenomation. 
  • Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. 
  • Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. 
  • Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. 
  • Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. 
  • Unraveling the Mystery of Troponin Elevation in Heart Failure. 
  • Use of guidelines-recommended management and outcomes among women and men with low-level troponin elevation: insights from CRUSADE. 
  • Use of the peak troponin value to differentiate myocardial infarction from reversible neurogenic left ventricular dysfunction associated with aneurysmal subarachnoid hemorrhage. 
  • Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. 
  • Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. 
  • Utility of observation units for young emergency department chest pain patients. 
  • cTnT1, a cardiac troponin T isoform, decreases myofilament tension and affects the left ventricular pressure waveform. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Limkakeng Jr., Alexander Tan, Professor of Emergency Medicine, Emergency Medicine
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology